Novo Nordisk's Billion-Dollar Buyback Meets a Pricing Squeeze and Digital Dominance in Obesity Market
Published on 05/21/2026 at 02:43 | Redaktion boerse-global.de
The Danish pharma giant has spent 4.17 billion Danish kroner repurchasing its own B-shares since February 4, 2026, yet its stock trades more than 44% below the 52-week high of over 70 euros. The contradiction is stark, but the logic behind the buyback is grounded in a strong first-quarter performance and a still-dominant franchise.
Investors have seen the shares claw back 16% over the past 30 days, landing at 38.85 euros. The repurchase program, which can run up to 15 billion kroner over twelve months under EU Safe Harbour rules, is scheduled to conclude by February 2027. Novo Nordisk already holds roughly 33 million treasury B-shares, representing 0.7% of its share capital. In the week of May 6–13 alone, it bought nearly 1.24 million shares for about 370 million kroner.
The buyback follows a surprisingly robust first quarter. Wegovy and Ozempic generated combined sales of 63.25 billion kroner, accounting for nearly 65% of total revenue. The oral version of Wegovy, launched in the US in January, added 2.25 billion kroner in the quarter and has already generated over 2 million prescriptions. Management responded by slightly lifting its full-year outlook, now expecting a 4% to 12% decline in revenue and operating profit at constant exchange rates, compared with the previous forecast of 5% to 13%. The underlying obesity business grew 22% on a currency-adjusted basis, but US revenues actually fell 11% as lower selling prices ate into volume gains.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That pricing pressure is set to intensify. The Trump administration plans to expand the TrumpRx direct-distribution programme, which offers drugs at reduced prices. Novo Nordisk has already struck a discount agreement with Washington to secure tariff exemptions, but a broader rollout could tighten existing price commitments. The company also faces rising investment costs and growing competition from Eli Lilly, whose Zepbound drug is a close rival in the obesity market.
A new digital dimension has emerged in this battle. According to an index measuring visibility in AI chatbots such as ChatGPT and Claude, Wegovy tops the list with a 19% share of responses, followed by Eli Lilly’s Zepbound and Wegovy’s sister drug Ozempic at 13%. For investors, the data suggests that patient searches are increasingly shaped by algorithms, potentially influencing prescribing behaviour even before patients enter a doctor’s office.
To reduce its dependence on the GLP-1 class, Novo Nordisk has initiated a Phase 1 trial of LX9851, an oral non-incretin candidate licensed from Lexicon Pharmaceuticals in March 2025. Lexicon has already received a $10 million milestone payment, with a second of the same amount possible later this year. The total potential value of the deal reaches $1 billion, underscoring how seriously Novo Nordisk is exploring alternative mechanisms. Final Phase 1 data are not expected before 2027.
For now, the market is watching whether the steep repurchase programme and strong prescription volumes can offset the headwinds from US pricing policy and margin erosion. The stock remains 44% below its peak, and the road to recovery depends not only on digital dominance and pipeline progress, but on Novo Nordisk’s ability to sustain pricing power in a fiercely competitive environment.
Ad
Novo Nordisk Stock: New Analysis - 21 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
